Maze Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 6, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Director Departure
On November 6, 2025, Sekar Kathiresan, a member of our board of directors, resigned from our board of directors and the committees thereof. Dr. Kathiresan’s departure was not a result of any disagreement with us over any of our operations, policies or practices.
Rule 10b5-1 Trading Plans
During the three months ended September 30, 2025, the following directors and/or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” in each case as defined in Item 408 of Regulation S-K:
| Character of Trading Arrangement | |||||||
|---|---|---|---|---|---|---|---|
| Action | Date of | Rule | Non-Rule | Nature of | Aggregate Number | Duration of Trading | |
| Name and Title | Taken | Action | 10b5-1* | 10b5-1** | Trading | of Securities | Arrangement(1) |
| Atul Dandekar, Chief Strategy & Business Officer | Adopted | September 29, 2025 | X | Sale | 155,000 | 12/29/2025-12/4/2026 | |
| Harold Bernstein, M.D., Ph.D, President, Research and Development and Chief Medical Officer | Adopted | September 29, 2025 | X | Sale | 323,635 | (2) | 12/29/2025-12/29/2026 |
| Amy Bachrodt, SVP, Finance | Adopted | September 29, 2025 | X | Sale | 56,000 | (2) | 12/29/2025-12/31/2026 |
| *Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. | |||||||
| **"Non-Rule 10b5-1 trading arrangement" as defined in Item 408(c) of Regulation S-K under the Exchange Act. | |||||||
| 1 The trading arrangement may expire on an earlier date if and when all transactions under the arrangement are completed. | |||||||
| 2 This amount represents the maximum total shares that could be sold under the plan. | |||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.